Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Assets Average (2017 - 2025)

UroGen Pharma's Assets Average history spans 8 years, with the latest figure at $192.8 million for Q4 2025.

  • For Q4 2025, Assets Average fell 34.4% year-over-year to $192.8 million; the TTM value through Dec 2025 reached $192.8 million, down 34.4%, while the annual FY2025 figure was $243.1 million, 4.77% up from the prior year.
  • Assets Average reached $192.8 million in Q4 2025 per URGN's latest filing, down from $196.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $293.8 million in Q4 2024 to a low of $104.2 million in Q2 2023.
  • Average Assets Average over 5 years is $176.7 million, with a median of $150.2 million recorded in 2022.
  • Peak YoY movement for Assets Average: crashed 40.59% in 2021, then soared 131.58% in 2024.
  • A 5-year view of Assets Average shows it stood at $127.2 million in 2021, then rose by 3.83% to $132.0 million in 2022, then surged by 40.84% to $186.0 million in 2023, then surged by 58.0% to $293.8 million in 2024, then crashed by 34.4% to $192.8 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Assets Average are $192.8 million (Q4 2025), $196.9 million (Q3 2025), and $228.2 million (Q2 2025).